Iasocholine (Fluorocholine (18f) Chloride)

Fluorocholine is taken up by cells via choline transporters and phosphorylated by choline kinase. The phosphorylated compound becomes trapped in cells with high membrane synthesis, emitting positrons from the fluorine‑18 isotope. PET scanners detect these emissions, producing images of metabolically active tissue.

The administered activity of Iasocholine is determined by the prescribing physician or nuclear medicine specialist based on patient weight, indication, and imaging protocol. Exact dosing is individualized and should follow local regulatory and institutional guidelines.

Iasocholine involves exposure to ionizing radiation, which may pose risks to a developing fetus or nursing infant. It should be avoided in pregnant or breastfeeding women unless the diagnostic benefit outweighs potential harm, and alternative imaging methods should be considered.

To request Iasocholine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with fluorodeoxyglucose (FDG), fluorocholine targets choline metabolism rather than glucose uptake, offering higher specificity for certain prostate and liver cancers. It may provide clearer lesion delineation in tumors with low FDG avidity, but selection depends on the clinical question and tumor type.

Iasocholine should be stored at ambient temperature, protected from light and moisture, and kept in its original sealed container. Because it contains a short‑half‑life radioisotope, it is supplied ready for use shortly before administration and should not be frozen or shaken.

Iasocholine is administered intravenously as a sterile solution. The injection is performed by qualified healthcare personnel, typically followed by a waiting period to allow tracer distribution before the PET scan begins, according to the imaging protocol.

The most serious risks include severe allergic reactions (anaphylaxis) and radiation‑related injury, particularly to the injection site or surrounding tissues. Patients should be monitored for immediate hypersensitivity signs, and radiation exposure should be justified by the clinical benefit.

Iasocholine should be avoided in individuals with known hypersensitivity to fluorocholine or any formulation components, in pregnant or breastfeeding women unless absolutely necessary, and in patients who have received other radiopharmaceuticals that could interfere with imaging interpretation.